"We are living in an exciting time for cancer pharmacology, where the fusion of multiple disciplines of basic and clinical science are creating effective, life-prolonging therapies for a growing number of malignancies. Historically, the first anticancer agents targeted molecules that are critical to the overall process of cell replications in both normal and malignant cells and, as such, were relatively non-discriminatory in their cytotoxicity. The revolution in molecular technology that began in the late 1980's is now being brought to bear on the structural design of agents that selectively…mehr
"We are living in an exciting time for cancer pharmacology, where the fusion of multiple disciplines of basic and clinical science are creating effective, life-prolonging therapies for a growing number of malignancies. Historically, the first anticancer agents targeted molecules that are critical to the overall process of cell replications in both normal and malignant cells and, as such, were relatively non-discriminatory in their cytotoxicity. The revolution in molecular technology that began in the late 1980's is now being brought to bear on the structural design of agents that selectively target tumor-related gene mutations and signaling pathway intermediaries in ways that may augment tumor cell death and spare underlying normal cell populations"--
Ashkan Emadi, MD, PhD is Professor of Medicine and Pharmacology, Associate Director of Clinical Research at the Marlene and Stewart Greenbaum Comprehensive Cancer, and Director of the Translational Genomics Laboratory at the University of Maryland School of Medicine in Baltimore, Maryland.
Inhaltsangabe
We dedicate this book to the chemists, biologists, pharmacologists, clinicians and clinical investigators, and patients and their families who continue to improve the lives of patients with cancer-and to science and its divinity. Contents Contributors Preface 1. Anticancer Drug Development: An Introduction 2. Alkylating Agents 3. Antimetabolites: Hydroxyurea, Pyrimidine and Purine Analogs, and L-Asparaginase 4. Antimetabolites: Antifolates 5. Antimitotics 6. DNA Repair, Apoptotic Pathways, CDK Inhibitors 7. Epigenetic Modulators 8. Differentiating Agents and Microenvironment 9. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer 10. Male Hormonal Therapies 11. Targeted Therapies (Small Molecules) 12. Monoclonal Antibodies Including Immunoconjugates and Cytokine-Directed Agents 13. Immunotherapeutics Including Vaccines, Bispecifics, CAR-T, and Checkpoint Inhibitors 14. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention 15. Transplant-Related Agents 16. Basic Drug Development With Structural Considerations 17. Integral Components in Development of Clinical Trials: PK/PD, Statistics, and Principles of Rational Combinatorial Therapies 18. Drug Approval and Regulatory Issues Index Contributors
We dedicate this book to the chemists, biologists, pharmacologists, clinicians and clinical investigators, and patients and their families who continue to improve the lives of patients with cancer-and to science and its divinity. Contents Contributors Preface 1. Anticancer Drug Development: An Introduction 2. Alkylating Agents 3. Antimetabolites: Hydroxyurea, Pyrimidine and Purine Analogs, and L-Asparaginase 4. Antimetabolites: Antifolates 5. Antimitotics 6. DNA Repair, Apoptotic Pathways, CDK Inhibitors 7. Epigenetic Modulators 8. Differentiating Agents and Microenvironment 9. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer 10. Male Hormonal Therapies 11. Targeted Therapies (Small Molecules) 12. Monoclonal Antibodies Including Immunoconjugates and Cytokine-Directed Agents 13. Immunotherapeutics Including Vaccines, Bispecifics, CAR-T, and Checkpoint Inhibitors 14. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention 15. Transplant-Related Agents 16. Basic Drug Development With Structural Considerations 17. Integral Components in Development of Clinical Trials: PK/PD, Statistics, and Principles of Rational Combinatorial Therapies 18. Drug Approval and Regulatory Issues Index Contributors
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
